Circulating Tumor DNA Analysis for Personalized Cancer Detection and Monitoring

Max Diehn, MD, PhD, Stanford University School of Medicine

Ran On Wednesday, September 9 | 8am PST, 11am EST

Request more information today from this free live interactive session!

Roche

Free To Attend!

The September Roche CDx News & Brews with Max Diehn, MD, PhD, Stanford University School of Medicine, covered;

Roche

Circulating Tumor DNA Analysis for Personalized Cancer Detection and Monitoring

While recent years have seen advances in diagnosis and treatment lead to improved survival rates for many early stage cancer types, there is an important need for earlier detection so that patients most at risk of relapse can avoid unnecessary
disease recurrence and progression.

Insights came from Dr. Diehn on the transformative potential of ctDNA as a biomarker enabling the detection, diagnosis and monitoring of disease for timely and targeted treatment interventions.

Key Topics Included:  

  • Recent evidence supporting ctDNA minimum residual disease (MRD) as a powerful prognostic marker in non-small cell lung cancer (NSCLC) and other cancers
  • Improved outcomes in ctDNA MRD+ NSCLC following consolidation immunotherapy
  • How ctDNA MRD is showing great promise for the personalization of therapies in adjuvant and consolidation settings

Following a Q&A with Dr. Diehn, attendees connected with key Roche executives and members of the Roche CDx team to learn how tailored solutions can support your needs at any stage in a drug development journey.

Who should attend?

This was an event for senior executives of innovative biotechs looking to refine trial design, increase identification of patient responders and accelerate delivery of the next generation of immunotherapies in areas of high unmet need. 

Members of the Roche CDx team also took part to learn how tailored solutions can support your needs at any stage in a drug development journey.

About the Speaker

Maximilian Diehn, MD, PhD

Associate Professor of Radiation Oncology

Stanford University

Maximilian Diehn, MD, PhD, is the CRK Faculty Scholar and Associate Professor of Radiation Oncology at Stanford University. He is the Vice Chair of Research of the Department of Radiation Oncology and the Division Chief of Radiation and Cancer Biology. He received his Bachelor’s Degree in Biochemical Sciences from Harvard College and his MD/PhD in Biophysics from Stanford University. He is a board certified Radiation Oncologist and specializes in the treatment of lung cancers. Dr. Diehn’s research program spans laboratory, translational, and clinical studies. His main areas of interest include liquid biopsies, lung cancer biology, and mechanisms of resistance to anti-cancer therapies including radiotherapy, immunotherapy, and targeted therapies. He has served on committees for a variety of national organizations including ASTRO, ASCO, AARC, and RSNA and is a Scientific Editor for Cancer Discovery. Dr. Diehn has received funding from organizations such as the NIH, Department of Defense, and Stand Up To Cancer and he has been recognized with a variety of awards, including the NIH Director’s New Innovator Award, the V Foundation Scholar Award, the Sidney Kimmel Scholar Award, the Doris Duke Clinical Scientist Development Award, and election into the American Society for Clinical Investigation.

Roche CDx News & Brews is an exclusive event series providing leaders in pharma and biotech with the opportunity to explore the latest innovations in technologies that facilitate the advancement of precision medicine.

These popular events have been adapted to a virtual format, so you can forge connections with key company and industry thought leaders and learn about diagnostic advances that have the potential to expedite end-to-end drug development from the comfort of your own home.